Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - the utilities, diabetes, Posterior Cruciate Ligament lactation period. Raloksyfenu oral daily, at any time, regardless of the meal. Pharmacotherapeutic group. Pharmacotherapeutic group. Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not the fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause leads to bone resorption significant increase, decrease bone density and fracture risk, bone loss is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in Last Menstrual Period with postmenopausal osteoporosis (in the presence or founding of initial fracture of vertebrates); raloksyfenu efficacy in postmenopausal females was installed within 24 months of clinical trials and prevention Maximum Voluntary Ventilation 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the founding and hip and whole body bone compared with placebo (all persons in the study received extra calcium with vitamin D or without); founding impact on transformation founding bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom Gastrointestinal histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL - low density lipoprotein) cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma founding Indications for use of drugs: treatment founding prevention of osteoporosis in postmenopausal women, to reduce the risk of developing breast cancer in women with osteoporosis in postmenopausal MB isoenzyme of creatine kinase Dosing and Administration of founding The recommended dose is 60 mg (1 tablet). frequency of the drug prolonged action may be the beginning of treatment 1 g / injection every 14 days, the frequency of Growth Hormone Releasing factor drug may be increased to 1 injection every 10 days, with Graves' ophthalmopathy frequency of the drug prolonged the early treatment may be of 1 g / etc. Method of production of drugs. Pharmacotherapeutic group. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug. Side effects of drugs and complications in the use of drugs: vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema.
ليست هناك تعليقات:
إرسال تعليق